论文部分内容阅读
目的 腹腔免疫化疗抗胃癌术后癌性腹水近期临床疗效及有关机理。方法 40例胃癌术后癌性腹水患者采用腹腔注射卡铂和肿瘤坏死因子α治疗 ,B超测定患者治疗前后腹水消褪率。结果 腹腔免疫化疗抗胃癌术后癌性腹水患者一疗程有效率 73 5 % ,且该治疗显著降低外周血中消化道癌相关抗原 (CCA)和sIL 2R含量 ;其褪腹水有效率高于单纯腹腔化疗和静脉化疗组。结论 卡铂和肿瘤坏死因子α具有协同抗癌作用 ,两者合用是治疗患者术后胃癌癌性腹水安全、简便、有效新方法
Objective To evaluate the short-term clinical efficacy and mechanism of intraperitoneal immunotherapy for cancer-resistance ascites after gastric cancer. Methods Forty patients with cancerous ascites after gastric cancer were treated with intraperitoneal injection of carboplatin and tumor necrosis factor-alpha. B-ultrasonography was used to measure the rate of dissipated ascites before and after treatment. RESULTS: The effective rate of peritoneal immuno-chemotherapy in patients with cancerous ascites after gastric cancer surgery was 73.5%, and this treatment significantly reduced the content of gastrointestinal cancer-associated antigen (CCA) and sIL 2R in peripheral blood; the efficacy of attenuating ascites was higher than that of abdominal cavity alone. Chemotherapy and intravenous chemotherapy group. Conclusion Carboplatin and tumor necrosis factor alpha have a synergistic anti-cancer effect. Their combination is a safe, simple and effective method for the treatment of gastric cancer ascites in patients with postoperative gastric cancer.